Weiguo Su - HUTCHMED Chief Scientific Officer, Executive Director
| H7T2 Stock | EUR 2.72 0.10 3.55% |
Insider
Weiguo Su is Chief Scientific Officer, Executive Director of HUTCHMED LS 1 since 2017.
| Age | 61 |
| Tenure | 7 years |
| Phone | 852 2128 1188 |
| Web | http://www.hutch-med.com |
HUTCHMED Management Efficiency
The company has return on total asset (ROA) of (0.1932) % which means that it has lost $0.1932 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2472) %, meaning that it generated substantial loss on money invested by shareholders. HUTCHMED's management efficiency ratios could be used to measure how well HUTCHMED manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Currie | Computer And Technologies | N/A | |
| Tetsuo Kashio | Casio Computer CoLtd | N/A | |
| Ivar Wulff | Lery Seafood Group | 49 | |
| Takashi Kashio | Casio Computer CoLtd | N/A | |
| Henning Beltestad | Lery Seafood Group | 55 | |
| Kazuhiro Kashio | Casio Computer CoLtd | 57 | |
| Ka Poon | Computer And Technologies | 56 | |
| Nobuyuki Mochinaga | Casio Computer CoLtd | N/A | |
| Shin Takano | Casio Computer CoLtd | N/A | |
| Hans Ljen | Lery Seafood Group | N/A | |
| Wai Cheung | Computer And Technologies | 58 | |
| Toshiyuki Yamagishi | Casio Computer CoLtd | N/A | |
| Siren Gronhaug | Lery Seafood Group | 58 | |
| Richard Wohl | Computer And Technologies | 64 | |
| Tetsuro Izumi | Casio Computer CoLtd | N/A | |
| Hiroshi Nakamura | Casio Computer CoLtd | N/A | |
| Allen Nicholson | Computer And Technologies | 56 | |
| Larry Zivelonghi | Computer And Technologies | N/A | |
| Sjur Malm | Lery Seafood Group | N/A | |
| King Leung | Computer And Technologies | 61 | |
| David Brager | Computer And Technologies | 55 | |
Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.19 |
HUTCHMED LS 1 Leadership Team
Elected by the shareholders, the HUTCHMED's board of directors comprises two types of representatives: HUTCHMED inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED's management team and ensure that shareholders' interests are well served. HUTCHMED's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edith Shih, Company Secretary, Non-Executive Director | ||
| Chig Cheng, Chief Financial Officer, Executive Director | ||
| May Wang, Senior Vice President - business development & strategic alliances | ||
| Mark Lee, Senior Vice President - Corporate Finance & Development | ||
| Karen Ferrante, Independent Non-Executive Director | ||
| Christian Hogg, Chief Executive Officer, Executive Director | ||
| Weiguo Su, Chief Scientific Officer, Executive Director | ||
| Shu Mok, Independent Non-Executive Director | ||
| Graeme Jack, Independent Non-Executive Director | ||
| Zhenping Wu, Senior Vice President - Pharmaceutical Sciences | ||
| Dan Eldar, Non-Executive Director | ||
| Simon To, Executive Chairman of the Board | ||
| Paul Carter, Senior Independent Non-Executive Director |
HUTCHMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HUTCHMED a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.64) % | |||
| Operating Margin | (0.95) % | |||
| Shares Outstanding | 864.77 M | |||
| Shares Owned By Insiders | 44.52 % | |||
| Shares Owned By Institutions | 54.43 % | |||
| Revenue | 400.81 M | |||
| Gross Profit | (201.19 M) | |||
| EBITDA | (373.29 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in HUTCHMED Stock
HUTCHMED financial ratios help investors to determine whether HUTCHMED Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HUTCHMED with respect to the benefits of owning HUTCHMED security.